Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review.
Motong Xu, Shuo Qiu, Jie Zhou et al.
✦ AI-curated · Sources linked
Case in brief
A patient with recurrent cervical squamous cell carcinoma and hepatic metastases initially received platinum-based chemotherapy with cadonilimab and bevacizumab, achieving a partial response after four cycles and a progression-free survival of 11 months. Upon disease progression, treatment with ivonescimab and albumin-bound paclitaxel was initiated, resulting in another partial response after two cycles, with low-grade adverse events and maintained quality of life.
What made this case unusual
This case is notable for demonstrating a significant response to ivonescimab in recurrent or metastatic cervical cancer after failure of first-line immunotherapy combined with anti-angiogenic therapy.
Diagnostic / clinical pearl
Clinicians should consider ivonescimab as a potential treatment option in later-line therapy for patients with recurrent or metastatic cervical cancer, especially after prior treatment failures.
Why it matters
This case highlights the potential of ivonescimab to provide clinical benefits in a challenging patient population, suggesting a novel therapeutic strategy for managing advanced cervical cancer.